Nothing Special   »   [go: up one dir, main page]

BR112012020791A2 - produção de 6'-o-sialillactose e intermediários - Google Patents

produção de 6'-o-sialillactose e intermediários

Info

Publication number
BR112012020791A2
BR112012020791A2 BR112012020791A BR112012020791A BR112012020791A2 BR 112012020791 A2 BR112012020791 A2 BR 112012020791A2 BR 112012020791 A BR112012020791 A BR 112012020791A BR 112012020791 A BR112012020791 A BR 112012020791A BR 112012020791 A2 BR112012020791 A2 BR 112012020791A2
Authority
BR
Brazil
Prior art keywords
sialillactose
intermediates
production
salts
trisaccharide
Prior art date
Application number
BR112012020791A
Other languages
English (en)
Inventor
Andreas Schroven
Christian Risinger
Christoph Röhrig
Ferenc Horvath
Gyula Dékany
Ignácio Pérez Figueroa
Ioannis Vrasidas
Istvan Bjza
Julien Boutet
Károly Ágoston
Lars Kröger
Markus Hederos
Piroska Kovács-Pénzes
Ágnes Ágoston
Original Assignee
Glycom As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycom As filed Critical Glycom As
Publication of BR112012020791A2 publication Critical patent/BR112012020791A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

produção de 6'-o-sialillactose e intermediários. a presente invenção refere-se a um método de preparação do trissacarídeo 6'-o-sialillactose (fórmula (i))) fórmula (i) ou sais do mesmo bem como intermediários na síntese e para uso de sais de 6'-o-sialillactose em composições farmacêuticas ou nutricionais.
BR112012020791A 2010-02-19 2011-02-21 produção de 6'-o-sialillactose e intermediários BR112012020791A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201070061 2010-02-19
PCT/DK2011/050052 WO2011100979A1 (en) 2010-02-19 2011-02-21 Production of 6'-o-sialyllactose and intermediates

Publications (1)

Publication Number Publication Date
BR112012020791A2 true BR112012020791A2 (pt) 2016-05-03

Family

ID=44482455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020791A BR112012020791A2 (pt) 2010-02-19 2011-02-21 produção de 6'-o-sialillactose e intermediários

Country Status (12)

Country Link
US (1) US9237764B2 (pt)
EP (1) EP2536736B1 (pt)
JP (1) JP2013519694A (pt)
KR (1) KR20120138772A (pt)
CN (1) CN102822186A (pt)
AU (1) AU2011217614A1 (pt)
BR (1) BR112012020791A2 (pt)
CA (1) CA2789821A1 (pt)
IL (1) IL220907A0 (pt)
MX (1) MX2012009306A (pt)
RU (1) RU2012140011A (pt)
WO (1) WO2011100979A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012007585A1 (en) * 2010-07-16 2012-01-19 Glycom A/S Derivatization of oligosaccharides
EP2859112A4 (en) 2012-06-08 2015-10-28 Glycom As PROCESS FOR THE PREPARATION OF OLIGOSACCHARIDES AND OLIGOSACCHARIDE GLYCOSIDES BY FERMENTATION
US9896470B2 (en) 2012-06-14 2018-02-20 Glycom A/S Enhancing the stability and purity and increasing the bioavailability of human milk oligosaccharides or precursors or blends thereof
GB201306687D0 (en) * 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated oligosaccharides
GB201306689D0 (en) 2013-04-12 2013-05-29 Glycom As Synthesis of sialylated/fucosylated human milk oligosaccharides
US10364449B2 (en) 2013-09-06 2019-07-30 Glycom A/S Fermentative production of oligosaccharides
SG11201703298SA (en) 2014-10-24 2017-05-30 Evolve Biosystems Inc Activated bifidobacteria and methods of use thereof
DK3209673T4 (da) 2014-10-24 2023-10-02 Glycom As Mixtures of human milk oligosaccharides
US11040050B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US11040049B2 (en) 2014-10-29 2021-06-22 Glycom A/S Composition comprising HMSs/HMOs and use thereof
US20160346303A1 (en) 2014-10-29 2016-12-01 Glycom A/S Synthetic composition and method for treating irritable bowel syndrome
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
WO2016091265A1 (en) 2014-12-08 2016-06-16 Glycom A/S Synthetic composition for treating metabolic disorders
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US10695359B2 (en) 2015-06-09 2020-06-30 Glycom A/S Ternary mixtures of 6′-SL, LNnT and LST c
WO2017046711A1 (en) 2015-09-14 2017-03-23 Glycom A/S Synthetic composition for microbiota modulation
WO2017086443A1 (ja) * 2015-11-18 2017-05-26 協和発酵バイオ株式会社 ６'－シアリルラクトースナトリウム塩の結晶およびその製造方法
US11432578B2 (en) 2015-12-15 2022-09-06 Glycom A/S Mixture of HMOs
WO2017144062A1 (en) 2016-02-24 2017-08-31 Glycom A/S Synthetic composition for microbiota modulation
WO2017152918A1 (en) 2016-03-07 2017-09-14 Glycom A/S Separation of oligosaccharides from fermentation broth
EP3458073B1 (en) 2016-05-19 2023-10-25 Glycom A/S Use of human milk oligosaccharides for treating migraine in patients with inflammatory bowel syndrome
CN109414447A (zh) 2016-06-24 2019-03-01 格礼卡姆股份公司 包括hmo的组合物、其制备和用于预防和/或治疗病毒和/或细菌感染的用途
CN106496290B (zh) * 2016-10-09 2019-01-18 济南山目生物医药科技有限公司 一种唾液酸供体的制备方法
EP3572087B9 (en) * 2017-01-23 2023-10-04 Cupione Co., Ltd. Composition for preventing or treating osteoarthritis containing sialyllactose or salt thereof as active ingredient
WO2018155995A1 (ko) * 2017-02-27 2018-08-30 한국생명공학연구원 시아릴락토오스를 유효성분으로 포함하는 항균용 조성물
EP3589139A4 (en) 2017-03-01 2020-12-23 Glycom A/S SYNTHETIC COMPOSITION FOR MICROBIOTE MODULATION
US11291677B2 (en) 2017-05-09 2022-04-05 Glycom A/S Synthetic composition for microbiota modulation
EP3630123A4 (en) 2017-05-24 2020-10-28 Glycom A/S SYNTHETIC COMPOSITION WITH ONE OR MORE HUMAN MILK OLIGOSACCHARIDES (HMOS)
US11541068B2 (en) 2017-05-24 2023-01-03 Glycom A/S HMO compositions and methods for reducing autism spectrum disorder symptoms
WO2019038668A1 (en) 2017-08-21 2019-02-28 Glycom A/S SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS
EP3456836A1 (en) 2017-09-13 2019-03-20 Glycom A/S Separation of sialylated oligosaccharides from fermentation broth
CA3081496A1 (en) 2017-11-02 2019-05-09 Glycom A/S Mixture of hmos for reducing or preventing fatigue
US11452736B2 (en) 2017-11-30 2022-09-27 Glycom A/S Mixture of HMOs for treating wheat sensitivity
KR20200096772A (ko) * 2017-12-08 2020-08-13 젠와인 바이오테크놀로지 게엠바하 분무건조된 시알릴락토스
CN111683666A (zh) 2017-12-22 2020-09-18 格礼卡姆股份公司 预防或减少伤害感受的包含hmo的组合物
EP3801558A4 (en) 2018-05-31 2022-03-09 Glycom A/S HMOS BLEND FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2021122103A1 (de) * 2019-12-18 2021-06-24 Basf Se Verfahren zur reduktion des säuregehaltes in humanen milcholigosacchariden
CN115298499A (zh) * 2020-03-20 2022-11-04 格礼卡姆股份公司 提供固体hmo产品的方法以及由此得到的固体hmo产品
EP4228436A1 (en) 2020-10-16 2023-08-23 Société des Produits Nestlé S.A. Nutritional composition comprising human milk oligosaccharides
AU2021376858A1 (en) 2020-11-10 2023-04-13 Société des Produits Nestlé S.A. Nutritional composition
WO2025008277A1 (en) 2023-07-06 2025-01-09 Societe Des Produits Nestle S.A. Combination for dietary management of gut health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990603A (en) 1986-07-04 1991-02-05 Mect Corporation Sialic acid derivatives and process therefor
JP3403205B2 (ja) 1996-09-17 2003-05-06 協和醗酵工業株式会社 糖ヌクレオチド類および複合糖質の製造法
FR2796082B1 (fr) 1999-07-07 2003-06-27 Centre Nat Rech Scient Procede de production d'oligosaccharides
US6288222B1 (en) 2000-02-16 2001-09-11 Neose Technologies, Inc. Method of filtration of a dairy stream
US6623954B1 (en) 2002-05-28 2003-09-23 Neose Technologies, Inc. Process for removal of phosphorous from a dairy stream
ATE468027T1 (de) * 2006-02-10 2010-06-15 Nestec Sa Oligosaccharidmischung
NL2001377C2 (nl) * 2008-03-14 2009-09-15 Friesland Brands Bv Werkwijze voor het isoleren van siaalzuur bevattende oligosachariden, alsmede de hiermee verkrijgbare siaalzuur bevattende oligosachariden bevatttende samenstellingen.
IT1394503B1 (it) 2009-04-06 2012-07-05 Inalco Spa Sali di 6'-sialillattosio e processo per la loro sintesi e per la sintesi di altri alfa-sialiloligosaccaridi.

Also Published As

Publication number Publication date
US9237764B2 (en) 2016-01-19
EP2536736A1 (en) 2012-12-26
US20130035481A1 (en) 2013-02-07
CA2789821A1 (en) 2011-08-25
EP2536736A4 (en) 2013-10-30
AU2011217614A1 (en) 2012-08-02
CN102822186A (zh) 2012-12-12
MX2012009306A (es) 2012-09-12
EP2536736B1 (en) 2017-08-16
RU2012140011A (ru) 2014-03-27
IL220907A0 (en) 2012-09-24
KR20120138772A (ko) 2012-12-26
WO2011100979A1 (en) 2011-08-25
JP2013519694A (ja) 2013-05-30

Similar Documents

Publication Publication Date Title
BR112012020791A2 (pt) produção de 6'-o-sialillactose e intermediários
CR20120264A (es) Compuestos
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
BR112014002922A2 (pt) compostos da fórmula i, processo de preparação de compostos da fórmula i, compostos da formula xii, viii e xi, composições agroquímicas, uso e semente
BR112013007362A2 (pt) composição farmacêutica
BR112015001327A2 (pt) complexo cristalino de 1-ciano-2-(4-ciclopropil-benzil) -4-(beta-d-glicopiranos-1-il) -benzeno, métodos para sua preparação e o uso do mesmo para preparar medicamentos
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
BR112012025714A2 (pt) uso de ácido 4-fenilbutírico e/ou sais do mesmo para aumentar a tolerância a estresse de plantas
BR112014013085A2 (pt) forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
BR112013011845B8 (pt) enxaguatório bucal compreendendo aminoácido básico e conservante e uso cosmético do enxaguatório bucal
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
UY32404A (es) 4-aril-butan-1,3-diamidas
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
CY1118514T1 (el) Μεθοδος για την παρασκευη πεμετρεξιδης και αλατος λυσινης αυτης
UY33668A (es) ?composiciones de las paredes celulares de ácido ribonucleico bacteriano, y métodos para elaborarlas y usarlas?.
BR112014018738A8 (pt) Métodos e intermediários para preparo de agentes farmacêuticos
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
BR112013028789A2 (pt) processo
IN2015DN00085A (pt)

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/702 (2006.01), C07H 1/00 (2006.01), C07H 3